Silverfin false false 30/06/2025 01/07/2024 30/06/2025 Jason Cawley 17/10/2019 Dr David Edward Jackson 15/12/2022 Alexander Roger William Marshall 28/11/2023 Iain Fenton Rae 17/10/2019 12 September 2025 no description of principal activity 07679157 2025-06-30 07679157 bus:Director1 2025-06-30 07679157 bus:Director2 2025-06-30 07679157 bus:Director3 2025-06-30 07679157 bus:Director4 2025-06-30 07679157 2024-06-30 07679157 core:CurrentFinancialInstruments 2025-06-30 07679157 core:CurrentFinancialInstruments 2024-06-30 07679157 core:ShareCapital 2025-06-30 07679157 core:ShareCapital 2024-06-30 07679157 core:SharePremium 2025-06-30 07679157 core:SharePremium 2024-06-30 07679157 core:RetainedEarningsAccumulatedLosses 2025-06-30 07679157 core:RetainedEarningsAccumulatedLosses 2024-06-30 07679157 core:OtherResidualIntangibleAssets 2024-06-30 07679157 core:OtherResidualIntangibleAssets 2025-06-30 07679157 core:OtherPropertyPlantEquipment 2024-06-30 07679157 core:OtherPropertyPlantEquipment 2025-06-30 07679157 bus:OrdinaryShareClass1 2025-06-30 07679157 bus:OrdinaryShareClass2 2025-06-30 07679157 2024-07-01 2025-06-30 07679157 bus:FilletedAccounts 2024-07-01 2025-06-30 07679157 bus:SmallEntities 2024-07-01 2025-06-30 07679157 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 07679157 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 07679157 bus:Director1 2024-07-01 2025-06-30 07679157 bus:Director2 2024-07-01 2025-06-30 07679157 bus:Director3 2024-07-01 2025-06-30 07679157 bus:Director4 2024-07-01 2025-06-30 07679157 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-07-01 2025-06-30 07679157 core:OtherPropertyPlantEquipment core:TopRangeValue 2024-07-01 2025-06-30 07679157 2023-07-01 2024-06-30 07679157 core:OtherResidualIntangibleAssets 2024-07-01 2025-06-30 07679157 core:OtherPropertyPlantEquipment 2024-07-01 2025-06-30 07679157 bus:OrdinaryShareClass1 2024-07-01 2025-06-30 07679157 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 07679157 bus:OrdinaryShareClass2 2024-07-01 2025-06-30 07679157 bus:OrdinaryShareClass2 2023-07-01 2024-06-30 07679157 bus:OrdinaryShareClass3 2024-07-01 2025-06-30 07679157 bus:OrdinaryShareClass3 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 07679157 (England and Wales)

# SEON DIAGNOSTICS LTD

### Unaudited Financial Statements
For the financial year ended 30 June 2025
Pages for filing with the registrar

SEON DIAGNOSTICS LTD

## Unaudited Financial Statements

For the financial year ended 30 June 2025

Contents

SEON DIAGNOSTICS LTD

## COMPANY INFORMATION

For the financial year ended 30 June 2025
SEON DIAGNOSTICS LTD

## COMPANY INFORMATION (continued)

For the financial year ended 30 June 2025

DIRECTORS | Jason Cawley
| Dr David Edward Jackson
| Alexander Roger William Marshall
| Iain Fenton Rae

REGISTERED OFFICE | Oxford House
| 15 - 17 Mount Ephraim Road
| Tunbridge Wells
| TN1 1EN
| United Kingdom

COMPANY NUMBER | 07679157 (England and Wales)

ACCOUNTANT | Synergee
| Pluto House
| 6 Vale Avenue
| Tunbridge Wells
| TN1 1DJ

SEON DIAGNOSTICS LTD

## BALANCE SHEET

As at 30 June 2025
SEON DIAGNOSTICS LTD

## BALANCE SHEET (continued)

As at 30 June 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Intangible assets | 3 | 2,551,782 |  | 2,126,863
Tangible assets | 4 | 5,306 |  | 8,860
|  | 2,557,088 |  | 2,135,723
Current assets |  |  |  |
Debtors | 5 | 143,001 |  | 57,307
Cash at bank and in hand | 6 | 68,661 |  | 11,871
|  | 211,662 |  | 69,178
Creditors: amounts falling due within one year | 7 | ( 187,229) |  | ( 155,203)
Net current assets/(liabilities) |  | 24,433 |  | (86,025)
Total assets less current liabilities |  | 2,581,521 |  | 2,049,698
Net assets |  | 2,581,521 |  | 2,049,698
Capital and reserves |  |  |  |
Called-up share capital | 8 | 74 |  | 44
Share premium account |  | 2,217,915 |  | 1,769,295
Profit and loss account |  | 363,532 |  | 280,359
Total shareholders' funds |  | 2,581,521 |  | 2,049,698

For the financial year ending 30 June 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Seon Diagnostics Ltd (registered number: 07679157) were approved and authorised for issue by the Board of Directors on 12 September 2025. They were signed on its behalf by:

Iain Fenton Rae Director |

SEON DIAGNOSTICS LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 June 2025
SEON DIAGNOSTICS LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 June 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Seon Diagnostics Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Oxford House, 15 - 17 Mount Ephraim Road, Tunbridge Wells, TN1 1EN, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.
Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Other intangible assets | not amortised

###### Research and development

Research expenditure is written off as incurred. Development expenditure is also written off, except where the directors are satisfied as to the technical, commercial and financial viability of individual projects. In such cases, the identifiable expenditure is capitalised as an intangible asset and amortised over the period during which the Company is expected to benefit. This period is between three and five years. Provision is made for any impairment.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. | 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

##### Government grants

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 6 |  | 8

#### 3. Intangible assets

| Other intangible assets |  | Total
| £ |  | £
Cost |  |  |
At 01 July 2024 | 2,126,863 |  | 2,126,863
Additions | 424,919 |  | 424,919
At 30 June 2025 | 2,551,782 |  | 2,551,782
Accumulated amortisation |  |  |
At 01 July 2024 | 0 |  | 0
At 30 June 2025 | 0 |  | 0
Net book value |  |  |
At 30 June 2025 | 2,551,782 |  | 2,551,782
At 30 June 2024 | 2,126,863 |  | 2,126,863

#### 4. Tangible assets

| Plant and machinery etc. |  | Total
| £ |  | £
Cost |  |  |
At 01 July 2024 | 27,109 |  | 27,109
At 30 June 2025 | 27,109 |  | 27,109
Accumulated depreciation |  |  |
At 01 July 2024 | 18,249 |  | 18,249
Charge for the financial year | 3,554 |  | 3,554
At 30 June 2025 | 21,803 |  | 21,803
Net book value |  |  |
At 30 June 2025 | 5,306 |  | 5,306
At 30 June 2024 | 8,860 |  | 8,860

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Other debtors | 143,001 |  | 57,307

#### 6. Cash and cash equivalents

| 2025 |  | 2024
| £ |  | £
Cash at bank and in hand | 68,661 |  | 11,871

#### 7. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Trade creditors | 29,708 |  | 58,954
Other taxation and social security | 7,667 |  | 22,881
Other creditors | 149,854 |  | 73,368
| 187,229 |  | 155,203

#### 8. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
68,586 Ordinary shares of £ 0.001 each (2024: nil shares) | 68.59 |  | 0
5,858 G Ordinary shares of £ 0.001 each (2024: nil shares) | 5.86 |  | 0
Nil ordinary shares (2024: 43,820 shares of £ 0.001 each) | 0 |  | 43.82
| 74.45 |  | 43.82